The European Medicines Agency (EMA) and the Institute for Medicines and Medical Devices of Montenegro (CINMED) have warned that drugs containing semaglutide can very rarely cause an adverse effect related to vision loss, specifically anterior ischemic optic neuropathy. In Montenegro, only one such drug, Ozempic, is registered but is currently not marketed. Patients who notice sudden loss or rapid deterioration of vision while using these drugs should immediately contact a doctor. If the condition is confirmed, the use of semaglutide should be discontinued. Information about these adverse effects will be updated according to EMA assessments.
Political Perspectives:
Left: Left-leaning sources tend to emphasize patient safety and the importance of transparent communication from pharmaceutical companies and regulatory agencies. They highlight the need for accessible healthcare and monitoring of drug side effects, advocating for patient rights and caution in the use of new medications.
Center: Center-leaning sources report the facts about the EMA’s findings and the regulatory status of semaglutide drugs in Montenegro, focusing on the rarity of the side effect and the procedural recommendations for patients and healthcare providers. They maintain a neutral tone, emphasizing the balance between drug benefits and risks.
Right: Right-leaning sources may focus on regulatory oversight and the responsibility of pharmaceutical companies, sometimes questioning the approval processes or emphasizing the importance of personal responsibility in medication use. They might also highlight the economic aspects of drug availability and market authorization.